🇺🇸 FDA
Patent

US 10376582

Buffer formulations for enhanced antibody stability

granted A61KA61K39/39591A61K47/02

Quick answer

US patent 10376582 (Buffer formulations for enhanced antibody stability) held by Outlook Therapeutics, Inc. expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Outlook Therapeutics, Inc.
Grant date
Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
82
CPC classes
A61K, A61K39/39591, A61K47/02, A61K47/12, A61K47/26